COMP <GO>
CRSP vs ADPT // RETURN ON INVESTED CAPITAL (ROIC)
CRISPR Therapeutics AG (NASDAQ) VS. Adaptive Biotechnologies Corporation (NASDAQ) • 15-METRIC TALLY: CRSP 3
— ADPT 8
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ADPT
LAST: $54.26 (+0.28%) • MKT CAP: $5.25B
roic
-30.60%
LAST: $28.17 (-0.70%) • MKT CAP: $4.50B
roic
-12.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. ADPT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | ADPT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -30.60% | -12.50% | -18.10 | ADPT | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | -1.09% | -5.50 | ADPT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -20.60% | -39.40 | ADPT | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -21.50% | -38.50 | ADPT | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 54.80% | -119.80 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.97 | 6.32 | +1.65 | CRSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | ADPT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.9 | 57.6 | -2.70 | ADPT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 1.01 | +0.11 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 26.0x | +2.00 | ADPT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.25B | $4.50B | $750.7M | CRSP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | ADPT REV | CRSP GROSS % | ADPT GROSS % | CRSP FCF | ADPT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $277.0M | — | 74.2% | -$345.9M | -$48.9M |
| FY 2024 | $37.3M | $179.0M | — | 59.7% | -$144.7M | -$98.9M |
| FY 2023 | $371.2M | $170.3M | — | — | -$277.1M | -$164.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
ADPT // BETA 1.01